These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 17435426

  • 1. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP, Brown GC, Brown MM.
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [Abstract] [Full Text] [Related]

  • 2. The burden of age-related macular degeneration: a value-based analysis.
    Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438
    [Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M.
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [Abstract] [Full Text] [Related]

  • 4. Quality of life and health economic assessments of age-related macular degeneration.
    Covert D, Berdeaux G, Mitchell J, Bradley C, Barnes R.
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S20-5. PubMed ID: 17240252
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomics and macular degeneration.
    Brown GC, Brown MM, Brown H, Godshalk AN.
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [Abstract] [Full Text] [Related]

  • 6. Information about age-related macular degeneration on the Internet.
    Stone TW, Jumper JM.
    South Med J; 2001 Jan; 94(1):22-5. PubMed ID: 11213937
    [Abstract] [Full Text] [Related]

  • 7. The burden of age-related macular degeneration: a value-based medicine analysis.
    Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Trans Am Ophthalmol Soc; 2005 Jan; 103():173-84; discussion 184-6. PubMed ID: 17057801
    [Abstract] [Full Text] [Related]

  • 8. Age-related macular degeneration: cost-of-illness issues.
    Oneill C, Jamison J, McCulloch D, Smith D.
    Drugs Aging; 2001 Jan; 18(4):233-41. PubMed ID: 11341471
    [Abstract] [Full Text] [Related]

  • 9. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.
    Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH, MICMAC (MICro-economics of MACular degeneration) Study Group.
    Drugs Aging; 2008 Jan; 25(3):255-68. PubMed ID: 18331076
    [Abstract] [Full Text] [Related]

  • 10. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 11. The cost of vision for vitreoretinal interventions.
    Smiddy WE.
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [Abstract] [Full Text] [Related]

  • 12. How to interpret a healthcare economic analysis.
    Brown MM, Brown GC.
    Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
    [Abstract] [Full Text] [Related]

  • 13. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL, Yu F.
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration.
    Schmier JK, Halpern MT, Covert D, Delgado J, Sharma S.
    Retina; 2006 Jan; 26(9):1056-62. PubMed ID: 17151494
    [Abstract] [Full Text] [Related]

  • 16. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 17. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.
    Delong LK, Culler SD, Saini SS, Beck LA, Chen SC.
    Arch Dermatol; 2008 Jan; 144(1):35-9. PubMed ID: 18209166
    [Abstract] [Full Text] [Related]

  • 18. Dietary prevention of age-related macular degeneration.
    Pratt S.
    J Am Optom Assoc; 1999 Jan; 70(1):39-47. PubMed ID: 10457680
    [Abstract] [Full Text] [Related]

  • 19. Relative cost of a line of vision in age-related macular degeneration.
    Smiddy WE.
    Ophthalmology; 2007 May; 114(5):847-54. PubMed ID: 17306878
    [Abstract] [Full Text] [Related]

  • 20. Erythropoietin as a novel therapeutic agent for atrophic age-related macular degeneration.
    Wang ZY, Zhao KK, Song ZM, Shen LJ, Qu J.
    Med Hypotheses; 2009 Apr; 72(4):448-50. PubMed ID: 19128888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.